Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2015 Jan 2;116(1):12-5.
doi: 10.1161/CIRCRESAHA.114.305495.

Allogeneic cell therapy: a new paradigm in therapeutics

Vasileios Karantalis  1 , Ivonne Hernandez Schulman  1 , Wayne Balkan  1 , Joshua M Hare  2
Affiliations
Editorial

Allogeneic cell therapy: a new paradigm in therapeutics

Vasileios Karantalis et al. Circ Res. .
No abstract available

Keywords: Editorials; allogeneic transplantation; autologous transplants; meta-analysis; stem cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mesenchymal stem cells are considered immunoprivileged due to their lack of expression of Major Histocompatibility Class II proteins and costimulatory molecules B7 and CD40 ligand and exert immunosuppressive actions through inhibition of innate and adaptive immunity.
Figure 2
Figure 2. Comparison of Autologous and Allogeneic stem cell therapy
Allogeneic stem cell therapy offers advantages over the autologous counterpart. The stem cells are derived from young healthy donors, eliminating any co-morbidities associated with disease states. Allogeneic cells grown and kept in stem cell banks so that they are available for immediate delivery.
See this image and copyright information in PMC

Comment on

References

    1. Karantalis V, Balkan W, Schulman IH, Hatzistergos KE, Hare JM. Cell-based therapy for prevention and reversal of myocardial remodeling. Am J Physiol Heart Circ Physiol. 2012;303:H256–270. - PMC - PubMed
    1. Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The tac-hft randomized trial. JAMA. 2014;311:62–73. - PMC - PubMed
    1. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The poseidon randomized trial. JAMA. 2012;308:2369–2379. - PMC - PubMed
    1. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB, Jr, Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277–2286. - PMC - PubMed
    1. Houtgraaf JH, den Dekker WK, van Dalen BM, Springeling T, de Jong R, van Geuns RJ, Geleijnse ML, Fernandez-Aviles F, Zijlsta F, Serruys PW, Duckers HJ. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with st-segment elevation myocardial infarction. J Am Coll Cardiol. 2012;59:539–540. - PubMed

MeSH terms